Get the Stockscreener App
7.96
0.10%
-0.03
After Hours:
7.80
-0.16
-2.01%
Candel Therapeutics Inc stock is traded at $7.96, with a volume of 1.23M.
It is down -0.10% in the last 24 hours and up +22.80% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$7.99
Open:
$8.13
24h Volume:
1.23M
Relative Volume:
0.67
Market Cap:
$583.23M
Revenue:
$31,000
Net Income/Loss:
$-38.18M
P/E Ratio:
-11.36
EPS:
-0.701
Net Cash Flow:
$-38.90M
1W Performance:
+4.21%
1M Performance:
+22.80%
6M Performance:
+72.78%
1Y Performance:
+47.00%
1-Day Range:
$7.955
$8.2998
1-Week Range:
$7.53
$8.34
52-Week Range:
$4.35
$9.27
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
7.96 | 585.43M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - simplywall.st
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - MSN
Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - Yahoo Finance
Candel Therapeutics reported better-than-feared Q1 loss – but all eyes turn to this pivotal event tomorrow - MSN
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs - Traders Union
Behavioral Patterns of CADL and Institutional Flows - Stock Traders Daily
Candel Therapeutics reports positive phase 3 prostate cancer trial data - MSN
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Raises Target Price to $9 - Moomoo
BofA raises Candel Therapeutics stock price target on prostate cancer data - Investing.com UK
BofA raises Candel Therapeutics stock price target on prostate cancer data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data - Dailyhunt
Candel reports extended phase 3 prostate cancer trial results - Investing.com UK
Candel Therapeutics Inc presents new extended follow-up phase 3 data for CAN-2409 in prostate cancer - Traders Union
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data - TipRanks
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting - The Manila Times
Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) - marketscreener.com
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409) - TradingView
Phase 3 prostate cancer data highlight Candel Therapeutics (NASDAQ: CADL) - Stock Titan
Candel Therapeutics : CADL AUA Investor Call final deck 3PM 5.14.26 IR - marketscreener.com
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25 - Moomoo
RTW Funds and Roderick Wong Hold 8.8% of Candel Therapeutics (NASDAQ: CADL) - Stock Titan
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Prostate cancer drug from Candel extends disease-free survival in phase 3 trial - Stock Titan
Candel Therapeutics : Website Candel May 2026 Corporate Presentation 230AM 05.14.26 IR - marketscreener.com
Candel Therapeutics, Inc. 10-Q Quarterly Report March 31, 2026: Financial Highlights, Risk Factors, and Company Overview - Minichart
Candel Therapeutics, Inc. celebrates Susan Stewart recognition in RAPSorg milestone honors - Traders Union
Candel Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Candel Therapeutics Reports Q1 2026 Results, Advances Towards BLA Submission for Aglatimagene in Prostate Cancer and Prepares Commercial Launch with EVERSANA - Minichart
Candel Therapeutics: Cash, Cash Equivalents of $194.8M, as of March 31, 2026, Expected Sufficient to Fund Co's Current Operating Plan Into Q1 2028 >CADL - Moomoo
Candel Therapeutics 1Q 2026: Net income $(8.9)M, EPS $(0.14) — 10-Q Summary - TradingView
Candel Therapeutics (NASDAQ: CADL) widens R&D loss but ends Q1 2026 with $194.8M cash - Stock Titan
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Globe and Mail
Candel Therapeutics reports Q1 2026 results; net loss $8.9M, cash $194.8M - TradingView
Candel Therapeutics 4Q Loss/Shr 14c >CADL - Moomoo
Candel Therapeutics reports Q1 loss - TradingView
Candel Therapeutics (NASDAQ: CADL) posts Q1 loss, ends quarter with $194.8M cash - Stock Titan
the real run is about to begin - Moomoo
Candel Therapeutics to Present at Upcoming Investor Conferences - marketscreener.com
TradingKey - TradingKey
U.S. Earnings Preview: Before Market Open May 12 - Moomoo
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat
Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope - Traders Union
Candel to discuss phase 3 prostate cancer trial data on May 15 - Investing.com UK
Candel to discuss phase 3 prostate cancer trial data on May 15 By Investing.com - Investing.com South Africa
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Option Exercise |
1.29 |
937 |
1,209 |
53,430 |
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):